|
[news 2003
- 2004]
Queens'
cancer research technology licensed to BD Biosciences
For immediate release
March 24, 2004
KINGSTON, ON - A cancer research technology developed
by two Queen's University scientists has been licensed
to BD Biosciences, a business segment of Becton Dickinson
and Company of Franklin Lakes, NJ by PARTEQ Innovations,
the technology transfer arm of Queen's.
The company signed a non-exclusive agreement with PARTEQ
for the rights to technology relating to multi-drug
resistance proteins (MRPs), first discovered and cloned
by Queen's cancer researchers Drs. Susan Cole and Roger
Deeley. Discovery Labware, a business unit of BD Biosciences,
will use the technology for the creation of commercial
drug screening services and products under the BD GentestT
brand.
The Queen's researchers' 1992 discovery has been critical
to the understanding of drug resistance in cancer chemotherapy.
Their research, which showed that these proteins act
as molecular 'pumps,' transporting compounds out of
cells, continues to be an important mechanism by which
the body deals with many types of drugs.
"This technology, which PARTEQ began protecting in 1992,
was a key breakthrough in understanding how human cancers
adapt to and resist chemotherapy," says John Molloy,
President and CEO of PARTEQ Innovations.
"As this latest agreement shows, MRP stands as one of
our most sought-after technologies. More than 10 years
after its discovery, it continues to contribute to the
advancement of cancer research."
About BD Biosciences-Discovery Labware:
Discovery Labware, a business unit of BD Biosciences,
develops, manufactures and markets products for tissue
culture, fluid handling, drug discovery and drug metabolism
under key brands such as BD GentestT. BD GentestT products
and services focus on the development of novel systems
for the in vitro analysis of xenobiotic (drug) metabolism
and toxicity.
About PARTEQ Innovations:
PARTEQ Innovations is the technology transfer arm of
Queen's University at Kingston, ON. A not-for-profit
organization, PARTEQ works with Queen's researchers
and the business and venture capital communities, helping
to bring the benefits of scientific discovery to the
public while returning proceeds to inventors and the
university.
Contact:
John Molloy,
President & CEO
PARTEQ Innovations
613. 533. 2342
www.parteqinnovations.com
|
